Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1844)	7/17/2007 3:49:37 PM
From: Jibacoa	Respond to of 3722

ESMC Was up 45% & it is still up 16.2% <g> bigcharts.marketwatch.com It announced today that it received clearance from the FDA to market its TRILOGY Analyzer. Bernard

To: Jibacoa who wrote (1844)	2/22/2008 12:19:55 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AGEN Is still holding above the $2 level after reporting yesterday its 4thQ results.<g> The stock is up 5.63% on volume of 63,459 about 1/3 of its ADV. bigcharts.marketwatch.com AGEN has now 4Qs of triple digit improvement on revenues & it also has been able to trim its losses. It said that its cash burn for 2007 was $27.5M, approximately 45% < the $50.1M in 2006. But the results on the coming 1st Q will probably not be looking as good in comparison, since the 2007 1stQ revenues of $2.3M look to be hard to match.<g> The EL for 2008 is around $0.75/shr vs. $0.81 in 2007 In Jan AGEN had a private placement of stock & warrants for $26.1M ending with $44.8M in cash. Its PIII of Oncophage C-100-12 in patients with nonmetastatic RCC showed that there was an improvement in recurrence-free survival, & there was a trend toward improved overall survival, which was not statistically significant.In Jun a marketing authorization application for Oncophage was filed in Russia,& AGEN has said that it plans to discuss with the EMEA in the 1stQ its plans for filing of a MAA for conditional authorization of Oncophage. AGEN has significant resistance at the $2.60 level before it can retest its Oct 25 spike to the $3.45 level bigcharts.marketwatch.com The Feb 2000 H was $71.50 <g> bigcharts.marketwatch.com Bernard